selexipag 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins receptors agonists, non-prostanoids | 5077 | 475086-01-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an oral prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin, indicated for the treatment of pulmonary arterial hypertension, selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag, selexipag and the active metabolite are selective for the IP receptor versus other prostanoid receptors (EP1-4, DP, FP and TP)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.80 | mg | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 21, 2015 | FDA | ACTELION PHARMS LTD | |
| Aug. 25, 2021 | PMDA | NIPPON SHINYAKU Co., Ltd |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pain in jaw | 2732.47 | 18.68 | 1212 | 70457 | 42284 | 63375069 |
| Headache | 2638.24 | 18.68 | 3381 | 68288 | 629860 | 62787493 |
| Diarrhoea | 1106.09 | 18.68 | 2459 | 69210 | 712907 | 62704446 |
| Myalgia | 1095.09 | 18.68 | 1068 | 70601 | 145461 | 63271892 |
| Dyspnoea | 1027.73 | 18.68 | 2279 | 69390 | 659034 | 62758319 |
| Fluid retention | 929.69 | 18.68 | 666 | 71003 | 59020 | 63358333 |
| Hospitalisation | 880.19 | 18.68 | 745 | 70924 | 84336 | 63333017 |
| Drug ineffective | 717.24 | 18.68 | 155 | 71514 | 1044610 | 62372743 |
| Dyspnoea exertional | 633.48 | 18.68 | 533 | 71136 | 59769 | 63357584 |
| Nausea | 587.72 | 18.68 | 2198 | 69471 | 852273 | 62565080 |
| Flushing | 511.18 | 18.68 | 521 | 71148 | 74566 | 63342787 |
| Therapy change | 488.28 | 18.68 | 202 | 71467 | 5879 | 63411474 |
| Right ventricular failure | 466.04 | 18.68 | 272 | 71397 | 16916 | 63400437 |
| Pain in extremity | 398.34 | 18.68 | 1038 | 70631 | 330448 | 63086905 |
| Transfusion | 394.65 | 18.68 | 234 | 71435 | 14983 | 63402370 |
| Death | 382.95 | 18.68 | 1105 | 70564 | 373276 | 63044077 |
| Pulmonary hypertension | 379.10 | 18.68 | 323 | 71346 | 36800 | 63380553 |
| Oxygen saturation decreased | 370.81 | 18.68 | 478 | 71191 | 88107 | 63329246 |
| Off label use | 319.82 | 18.68 | 183 | 71486 | 674279 | 62743074 |
| Oxygen consumption increased | 298.27 | 18.68 | 125 | 71544 | 3759 | 63413594 |
| Unevaluable event | 291.84 | 18.68 | 324 | 71345 | 51062 | 63366291 |
| Hypervolaemia | 277.42 | 18.68 | 241 | 71428 | 28172 | 63389181 |
| Dizziness | 271.72 | 18.68 | 1080 | 70589 | 428845 | 62988508 |
| Hypotension | 270.87 | 18.68 | 797 | 70872 | 271807 | 63145546 |
| Infusion related reaction | 261.10 | 18.68 | 3 | 71666 | 245518 | 63171835 |
| Toxicity to various agents | 250.59 | 18.68 | 6 | 71663 | 247244 | 63170109 |
| Decreased appetite | 238.89 | 18.68 | 723 | 70946 | 250329 | 63167024 |
| Maternal exposure during pregnancy | 228.32 | 18.68 | 4 | 71665 | 220058 | 63197295 |
| Drug hypersensitivity | 216.04 | 18.68 | 44 | 71625 | 310643 | 63106710 |
| Pulmonary arterial pressure increased | 214.99 | 18.68 | 97 | 71572 | 3498 | 63413855 |
| Nasal congestion | 210.96 | 18.68 | 312 | 71357 | 65348 | 63352005 |
| Alopecia | 205.35 | 18.68 | 63 | 71606 | 337473 | 63079880 |
| Treatment failure | 204.92 | 18.68 | 4 | 71665 | 199039 | 63218314 |
| Therapeutic product effect decreased | 202.54 | 18.68 | 3 | 71666 | 193184 | 63224169 |
| Rash | 200.53 | 18.68 | 203 | 71466 | 560668 | 62856685 |
| Catheterisation cardiac | 195.09 | 18.68 | 98 | 71571 | 4505 | 63412848 |
| Rheumatoid arthritis | 193.87 | 18.68 | 28 | 71641 | 253791 | 63163562 |
| Malaise | 188.50 | 18.68 | 947 | 70722 | 415007 | 63002346 |
| Arthropathy | 176.77 | 18.68 | 27 | 71642 | 234765 | 63182588 |
| Pulmonary arterial hypertension | 176.34 | 18.68 | 169 | 71500 | 22408 | 63394945 |
| Glossodynia | 175.09 | 18.68 | 6 | 71663 | 178870 | 63238483 |
| Cardiac failure | 173.77 | 18.68 | 339 | 71330 | 88803 | 63328550 |
| Neutropenia | 170.84 | 18.68 | 6 | 71663 | 174999 | 63242354 |
| Oedema | 168.57 | 18.68 | 353 | 71316 | 97269 | 63320084 |
| Drug interaction | 160.14 | 18.68 | 32 | 71637 | 229099 | 63188254 |
| Hepatic enzyme increased | 159.99 | 18.68 | 20 | 71649 | 202308 | 63215045 |
| Feeling abnormal | 155.87 | 18.68 | 443 | 71226 | 147949 | 63269404 |
| Concomitant disease aggravated | 151.61 | 18.68 | 106 | 71563 | 9006 | 63408347 |
| Hypersensitivity | 149.16 | 18.68 | 72 | 71597 | 292613 | 63124740 |
| Oedema peripheral | 142.41 | 18.68 | 504 | 71165 | 189007 | 63228346 |
| Scleroderma | 138.99 | 18.68 | 83 | 71586 | 5379 | 63411974 |
| Product dose omission issue | 134.34 | 18.68 | 572 | 71097 | 233741 | 63183612 |
| Palpitations | 132.65 | 18.68 | 351 | 71318 | 112419 | 63304934 |
| Brain natriuretic peptide increased | 132.09 | 18.68 | 79 | 71590 | 5134 | 63412219 |
| Syncope | 127.70 | 18.68 | 355 | 71314 | 117030 | 63300323 |
| Chest pain | 127.52 | 18.68 | 532 | 71137 | 215427 | 63201926 |
| Joint swelling | 125.75 | 18.68 | 111 | 71558 | 327555 | 63089798 |
| Pericarditis | 120.29 | 18.68 | 7 | 71662 | 131572 | 63285781 |
| Vomiting | 119.56 | 18.68 | 1056 | 70613 | 558561 | 62858792 |
| Stomatitis | 116.53 | 18.68 | 11 | 71658 | 138714 | 63278639 |
| Pneumonia | 113.52 | 18.68 | 892 | 70777 | 455875 | 62961478 |
| Systemic lupus erythematosus | 111.67 | 18.68 | 48 | 71621 | 208870 | 63208483 |
| Wound | 111.55 | 18.68 | 24 | 71645 | 163239 | 63254114 |
| Oxygen therapy | 109.16 | 18.68 | 52 | 71617 | 2126 | 63415227 |
| Therapeutic product effect incomplete | 107.52 | 18.68 | 9 | 71660 | 125047 | 63292306 |
| Pulmonary oedema | 107.26 | 18.68 | 209 | 71460 | 54664 | 63362689 |
| Blister | 107.18 | 18.68 | 11 | 71658 | 129803 | 63287550 |
| Hypoxia | 105.24 | 18.68 | 218 | 71451 | 59574 | 63357779 |
| Abdominal distension | 99.20 | 18.68 | 267 | 71402 | 86348 | 63331005 |
| Intentional product use issue | 97.82 | 18.68 | 14 | 71655 | 127878 | 63289475 |
| Thrombocytopenia | 95.86 | 18.68 | 26 | 71643 | 151131 | 63266222 |
| Product use issue | 95.55 | 18.68 | 66 | 71603 | 220454 | 63196899 |
| Impaired healing | 95.13 | 18.68 | 5 | 71664 | 102537 | 63314816 |
| Walking distance test abnormal | 93.44 | 18.68 | 32 | 71637 | 542 | 63416811 |
| Discomfort | 91.77 | 18.68 | 37 | 71632 | 167337 | 63250016 |
| Psoriatic arthropathy | 89.76 | 18.68 | 3 | 71666 | 91517 | 63325836 |
| Hypertension | 89.75 | 18.68 | 110 | 71559 | 279193 | 63138160 |
| Helicobacter infection | 87.75 | 18.68 | 4 | 71665 | 92781 | 63324572 |
| Pulmonary veno-occlusive disease | 85.81 | 18.68 | 36 | 71633 | 1085 | 63416268 |
| Blood pressure decreased | 84.28 | 18.68 | 210 | 71459 | 64812 | 63352541 |
| Product use in unapproved indication | 83.87 | 18.68 | 49 | 71620 | 179031 | 63238322 |
| Lung transplant | 83.43 | 18.68 | 49 | 71620 | 3079 | 63414274 |
| Acute kidney injury | 83.31 | 18.68 | 105 | 71564 | 263310 | 63154043 |
| Musculoskeletal stiffness | 83.01 | 18.68 | 53 | 71616 | 184565 | 63232788 |
| Dyspepsia | 82.06 | 18.68 | 278 | 71391 | 101918 | 63315435 |
| Malignant neoplasm progression | 79.47 | 18.68 | 3 | 71666 | 82118 | 63335235 |
| Exposure during pregnancy | 76.55 | 18.68 | 40 | 71629 | 155507 | 63261846 |
| Blood cholesterol increased | 75.01 | 18.68 | 9 | 71660 | 94023 | 63323330 |
| Neck pain | 74.70 | 18.68 | 209 | 71460 | 69109 | 63348244 |
| Epistaxis | 73.25 | 18.68 | 214 | 71455 | 72511 | 63344842 |
| Ascites | 72.25 | 18.68 | 149 | 71520 | 40579 | 63376774 |
| Faeces soft | 71.69 | 18.68 | 56 | 71613 | 5636 | 63411717 |
| N-terminal prohormone brain natriuretic peptide increased | 71.55 | 18.68 | 39 | 71630 | 2122 | 63415231 |
| Mobility decreased | 71.09 | 18.68 | 24 | 71645 | 121135 | 63296218 |
| Abdominal pain upper | 71.08 | 18.68 | 437 | 71232 | 206007 | 63211346 |
| Pericardial effusion | 70.69 | 18.68 | 124 | 71545 | 29934 | 63387419 |
| Transplant evaluation | 70.63 | 18.68 | 32 | 71637 | 1165 | 63416188 |
| Chest discomfort | 70.44 | 18.68 | 278 | 71391 | 109691 | 63307662 |
| Dialysis | 70.19 | 18.68 | 72 | 71597 | 10355 | 63406998 |
| Psoriasis | 70.16 | 18.68 | 8 | 71661 | 86949 | 63330404 |
| Urticaria | 69.99 | 18.68 | 51 | 71618 | 165751 | 63251602 |
| Cough | 69.42 | 18.68 | 566 | 71103 | 292177 | 63125176 |
| Dyspnoea at rest | 69.14 | 18.68 | 48 | 71621 | 4031 | 63413322 |
| Pruritus | 68.63 | 18.68 | 196 | 71473 | 361257 | 63056096 |
| Lower respiratory tract infection | 68.15 | 18.68 | 32 | 71637 | 132275 | 63285078 |
| Leukopenia | 68.00 | 18.68 | 5 | 71664 | 77285 | 63340068 |
| Therapy non-responder | 66.77 | 18.68 | 213 | 71456 | 75688 | 63341665 |
| Drug abuse | 65.83 | 18.68 | 4 | 71665 | 72514 | 63344839 |
| Drug titration error | 64.91 | 18.68 | 27 | 71642 | 796 | 63416557 |
| Migraine | 63.57 | 18.68 | 258 | 71411 | 103088 | 63314265 |
| Pain | 62.80 | 18.68 | 1178 | 70491 | 739450 | 62677903 |
| Infusion site pain | 62.73 | 18.68 | 86 | 71583 | 16783 | 63400570 |
| Confusional state | 62.24 | 18.68 | 107 | 71562 | 236273 | 63181080 |
| Bedridden | 61.51 | 18.68 | 69 | 71600 | 10982 | 63406371 |
| Hospice care | 61.21 | 18.68 | 59 | 71610 | 7873 | 63409480 |
| Asthma | 61.00 | 18.68 | 34 | 71635 | 127527 | 63289826 |
| Cardioversion | 59.86 | 18.68 | 29 | 71640 | 1231 | 63416122 |
| Injection site pain | 58.69 | 18.68 | 37 | 71632 | 129763 | 63287590 |
| Catheter site pain | 58.37 | 18.68 | 46 | 71623 | 4689 | 63412664 |
| Extra dose administered | 58.23 | 18.68 | 52 | 71617 | 6298 | 63411055 |
| Paracentesis | 57.45 | 18.68 | 26 | 71643 | 944 | 63416409 |
| Disease complication | 57.31 | 18.68 | 39 | 71630 | 3170 | 63414183 |
| Type 2 diabetes mellitus | 56.56 | 18.68 | 4 | 71665 | 63864 | 63353489 |
| Overdose | 56.01 | 18.68 | 30 | 71639 | 115048 | 63302305 |
| C-reactive protein increased | 55.14 | 18.68 | 19 | 71650 | 94688 | 63322665 |
| Condition aggravated | 54.90 | 18.68 | 694 | 70975 | 401523 | 63015830 |
| Productive cough | 54.33 | 18.68 | 176 | 71493 | 63032 | 63354321 |
| Liver injury | 53.00 | 18.68 | 4 | 71665 | 60516 | 63356837 |
| Osteoarthritis | 52.36 | 18.68 | 21 | 71648 | 95322 | 63322031 |
| Head discomfort | 52.33 | 18.68 | 70 | 71599 | 13345 | 63404008 |
| Cognitive disorder | 50.90 | 18.68 | 3 | 71666 | 55812 | 63361541 |
| Dizziness postural | 49.77 | 18.68 | 51 | 71618 | 7325 | 63410028 |
| Back pain | 49.36 | 18.68 | 485 | 71184 | 263660 | 63153693 |
| Irritable bowel syndrome | 48.91 | 18.68 | 16 | 71653 | 82396 | 63334957 |
| Atrial septal defect repair | 48.82 | 18.68 | 16 | 71653 | 235 | 63417118 |
| Catheter management | 47.95 | 18.68 | 34 | 71635 | 2953 | 63414400 |
| Left ventricular failure | 47.12 | 18.68 | 44 | 71625 | 5643 | 63411710 |
| Heart rate increased | 47.06 | 18.68 | 221 | 71448 | 94017 | 63323336 |
| Coma | 47.04 | 18.68 | 8 | 71661 | 64356 | 63352997 |
| Electrocardiogram QT prolonged | 46.73 | 18.68 | 6 | 71663 | 59524 | 63357829 |
| Presyncope | 46.19 | 18.68 | 99 | 71570 | 27686 | 63389667 |
| Deep vein thrombosis | 45.14 | 18.68 | 19 | 71650 | 83781 | 63333572 |
| Insomnia | 45.08 | 18.68 | 405 | 71264 | 214847 | 63202506 |
| Weight decreased | 44.51 | 18.68 | 493 | 71176 | 276305 | 63141048 |
| Muscle spasms | 44.28 | 18.68 | 315 | 71354 | 155835 | 63261518 |
| Pulmonary arterial pressure abnormal | 44.11 | 18.68 | 18 | 71651 | 505 | 63416848 |
| Hyponatraemia | 43.94 | 18.68 | 37 | 71632 | 111863 | 63305490 |
| Catheter placement | 43.77 | 18.68 | 29 | 71640 | 2255 | 63415098 |
| Peripheral swelling | 43.37 | 18.68 | 475 | 71194 | 265467 | 63151886 |
| Multiple sclerosis relapse | 43.03 | 18.68 | 3 | 71666 | 48475 | 63368878 |
| Seizure | 42.80 | 18.68 | 52 | 71617 | 132582 | 63284771 |
| Injury | 42.11 | 18.68 | 15 | 71654 | 73232 | 63344121 |
| Injection site erythema | 41.48 | 18.68 | 21 | 71648 | 83153 | 63334200 |
| Cardiac disorder | 41.44 | 18.68 | 139 | 71530 | 50677 | 63366676 |
| Injection site reaction | 41.20 | 18.68 | 8 | 71661 | 58516 | 63358837 |
| Mineral supplementation | 40.98 | 18.68 | 19 | 71650 | 730 | 63416623 |
| Disease progression | 40.41 | 18.68 | 257 | 71412 | 122501 | 63294852 |
| Haemoptysis | 39.57 | 18.68 | 95 | 71574 | 28631 | 63388722 |
| White blood cell count decreased | 39.37 | 18.68 | 60 | 71609 | 139044 | 63278309 |
| Rehabilitation therapy | 39.21 | 18.68 | 24 | 71645 | 1626 | 63415727 |
| Suicidal ideation | 39.06 | 18.68 | 11 | 71658 | 62410 | 63354943 |
| Rhabdomyolysis | 38.21 | 18.68 | 3 | 71666 | 43948 | 63373405 |
| Depression | 37.63 | 18.68 | 106 | 71563 | 196386 | 63220967 |
| Fibromyalgia | 37.63 | 18.68 | 22 | 71647 | 80398 | 63336955 |
| General physical health deterioration | 37.59 | 18.68 | 110 | 71559 | 201292 | 63216061 |
| Metapneumovirus infection | 37.52 | 18.68 | 20 | 71649 | 1040 | 63416313 |
| Catheter site erythema | 37.21 | 18.68 | 34 | 71635 | 4242 | 63413111 |
| Right ventricular enlargement | 37.19 | 18.68 | 14 | 71655 | 315 | 63417038 |
| Oxygen saturation abnormal | 36.59 | 18.68 | 31 | 71638 | 3498 | 63413855 |
| Agitation | 36.53 | 18.68 | 11 | 71658 | 59746 | 63357607 |
| Ill-defined disorder | 36.00 | 18.68 | 24 | 71645 | 81731 | 63335622 |
| Endarterectomy | 35.11 | 18.68 | 12 | 71657 | 202 | 63417151 |
| Right ventricular dysfunction | 34.63 | 18.68 | 23 | 71646 | 1796 | 63415557 |
| Pancytopenia | 34.57 | 18.68 | 35 | 71634 | 96898 | 63320455 |
| Emergency care | 34.50 | 18.68 | 19 | 71650 | 1055 | 63416298 |
| Catheterisation cardiac abnormal | 34.21 | 18.68 | 12 | 71657 | 219 | 63417134 |
| Exercise tolerance decreased | 33.50 | 18.68 | 36 | 71633 | 5461 | 63411892 |
| Right-to-left cardiac shunt | 32.96 | 18.68 | 12 | 71657 | 245 | 63417108 |
| Haemodynamic test abnormal | 32.71 | 18.68 | 8 | 71661 | 36 | 63417317 |
| Drug intolerance | 32.24 | 18.68 | 210 | 71459 | 308451 | 63108902 |
| Facial pain | 32.19 | 18.68 | 49 | 71620 | 10512 | 63406841 |
| Nocturnal dyspnoea | 32.19 | 18.68 | 19 | 71650 | 1205 | 63416148 |
| Atrial flutter | 32.16 | 18.68 | 47 | 71622 | 9725 | 63407628 |
| Haemoglobin decreased | 32.12 | 18.68 | 277 | 71392 | 145208 | 63272145 |
| Depressed level of consciousness | 31.97 | 18.68 | 15 | 71654 | 62063 | 63355290 |
| Iron deficiency anaemia | 31.88 | 18.68 | 70 | 71599 | 19899 | 63397454 |
| Therapeutic response decreased | 31.48 | 18.68 | 15 | 71654 | 61510 | 63355843 |
| Haemorrhoidal haemorrhage | 31.47 | 18.68 | 31 | 71638 | 4248 | 63413105 |
| Hyperkalaemia | 31.33 | 18.68 | 11 | 71658 | 54192 | 63363161 |
| Cardiac ablation | 31.26 | 18.68 | 20 | 71649 | 1465 | 63415888 |
| Flatulence | 31.06 | 18.68 | 98 | 71571 | 34604 | 63382749 |
| Cardiac failure high output | 30.96 | 18.68 | 12 | 71657 | 293 | 63417060 |
| Bursitis | 30.92 | 18.68 | 3 | 71666 | 37038 | 63380315 |
| Dysentery | 30.87 | 18.68 | 17 | 71652 | 944 | 63416409 |
| Blood pressure increased | 30.60 | 18.68 | 88 | 71581 | 161974 | 63255379 |
| Renal disorder | 30.33 | 18.68 | 94 | 71575 | 32880 | 63384473 |
| Infection | 29.85 | 18.68 | 145 | 71524 | 229028 | 63188325 |
| Vascular device infection | 29.82 | 18.68 | 39 | 71630 | 7273 | 63410080 |
| Pulmonary embolism | 29.61 | 18.68 | 54 | 71615 | 116630 | 63300723 |
| Intentional product misuse | 29.46 | 18.68 | 16 | 71653 | 60901 | 63356452 |
| Neuropathy peripheral | 29.39 | 18.68 | 52 | 71617 | 113615 | 63303738 |
| Wrong dose | 29.34 | 18.68 | 18 | 71651 | 1225 | 63416128 |
| Bradycardia | 29.01 | 18.68 | 24 | 71645 | 73203 | 63344150 |
| Hallucination | 28.61 | 18.68 | 13 | 71656 | 54804 | 63362549 |
| Blood pressure systolic increased | 28.48 | 18.68 | 9 | 71660 | 47388 | 63369965 |
| Influenza | 28.33 | 18.68 | 215 | 71454 | 108507 | 63308846 |
| Medication error | 27.92 | 18.68 | 12 | 71657 | 52272 | 63365081 |
| Hypoaesthesia | 27.89 | 18.68 | 97 | 71572 | 168296 | 63249057 |
| Systemic scleroderma | 27.84 | 18.68 | 16 | 71653 | 965 | 63416388 |
| Acute respiratory failure | 27.82 | 18.68 | 94 | 71575 | 34391 | 63382962 |
| Adverse event | 27.77 | 18.68 | 150 | 71519 | 67409 | 63349944 |
| Pulmonary congestion | 27.74 | 18.68 | 61 | 71608 | 17357 | 63399996 |
| Plasma cell myeloma | 27.28 | 18.68 | 4 | 71665 | 35901 | 63381452 |
| Mouth ulceration | 26.69 | 18.68 | 3 | 71666 | 32981 | 63384372 |
| Catheter site infection | 26.19 | 18.68 | 30 | 71639 | 4884 | 63412469 |
| Catheter site discharge | 25.77 | 18.68 | 20 | 71649 | 1993 | 63415360 |
| Angioedema | 25.63 | 18.68 | 11 | 71658 | 47954 | 63369399 |
| Localised oedema | 25.62 | 18.68 | 31 | 71638 | 5347 | 63412006 |
| Prescribed overdose | 25.50 | 18.68 | 4 | 71665 | 34149 | 63383204 |
| Intracardiac pressure increased | 25.42 | 18.68 | 7 | 71662 | 54 | 63417299 |
| Gout | 25.25 | 18.68 | 50 | 71619 | 13221 | 63404132 |
| Knee arthroplasty | 25.12 | 18.68 | 15 | 71654 | 54191 | 63363162 |
| Loss of consciousness | 25.08 | 18.68 | 223 | 71446 | 117898 | 63299455 |
| Swelling | 25.02 | 18.68 | 195 | 71474 | 275183 | 63142170 |
| Pleural effusion | 24.66 | 18.68 | 185 | 71484 | 93025 | 63324328 |
| Metabolic acidosis | 24.62 | 18.68 | 10 | 71659 | 45059 | 63372294 |
| Contusion | 24.46 | 18.68 | 87 | 71582 | 149957 | 63267396 |
| Cardiac operation | 24.45 | 18.68 | 24 | 71645 | 3274 | 63414079 |
| Tracheostomy | 24.37 | 18.68 | 13 | 71656 | 677 | 63416676 |
| Abdominal cavity drainage | 24.14 | 18.68 | 11 | 71658 | 406 | 63416947 |
| Blood creatine phosphokinase increased | 24.04 | 18.68 | 3 | 71666 | 30427 | 63386926 |
| Fatigue | 24.02 | 18.68 | 1228 | 70441 | 886800 | 62530553 |
| Alanine aminotransferase increased | 23.76 | 18.68 | 51 | 71618 | 103719 | 63313634 |
| Cardiac flutter | 23.53 | 18.68 | 26 | 71643 | 4070 | 63413283 |
| Liver transplant | 23.50 | 18.68 | 20 | 71649 | 2271 | 63415082 |
| Cardiac pacemaker insertion | 23.37 | 18.68 | 26 | 71643 | 4100 | 63413253 |
| Central venous catheterisation | 23.27 | 18.68 | 21 | 71648 | 2578 | 63414775 |
| Cardiac output increased | 23.17 | 18.68 | 9 | 71660 | 221 | 63417132 |
| Retching | 22.99 | 18.68 | 51 | 71618 | 14594 | 63402759 |
| Right ventricular dilatation | 22.87 | 18.68 | 16 | 71653 | 1360 | 63415993 |
| Concomitant disease progression | 22.65 | 18.68 | 19 | 71650 | 2115 | 63415238 |
| Injection site swelling | 22.27 | 18.68 | 13 | 71656 | 47559 | 63369794 |
| Sinusitis | 22.25 | 18.68 | 157 | 71512 | 226496 | 63190857 |
| Delirium | 22.03 | 18.68 | 15 | 71654 | 50526 | 63366827 |
| Swollen tongue | 22.02 | 18.68 | 6 | 71663 | 34794 | 63382559 |
| Stent placement | 21.85 | 18.68 | 24 | 71645 | 3731 | 63413622 |
| Drug-induced liver injury | 21.85 | 18.68 | 9 | 71660 | 40213 | 63377140 |
| Pyrexia | 21.75 | 18.68 | 387 | 71282 | 470091 | 62947262 |
| Lactic acidosis | 21.73 | 18.68 | 8 | 71661 | 38279 | 63379074 |
| Wrong technique in product usage process | 21.67 | 18.68 | 23 | 71646 | 62317 | 63355036 |
| Injection site pruritus | 21.59 | 18.68 | 12 | 71657 | 45104 | 63372249 |
| Cardiac monitoring | 21.55 | 18.68 | 5 | 71664 | 17 | 63417336 |
| Terminal state | 21.54 | 18.68 | 19 | 71650 | 2263 | 63415090 |
| Product supply issue | 21.53 | 18.68 | 17 | 71652 | 1738 | 63415615 |
| Pulmonary pain | 21.52 | 18.68 | 23 | 71646 | 3467 | 63413886 |
| N-terminal prohormone brain natriuretic peptide | 21.49 | 18.68 | 6 | 71663 | 49 | 63417304 |
| Hepatitis | 21.46 | 18.68 | 9 | 71660 | 39779 | 63377574 |
| Influenza like illness | 21.42 | 18.68 | 139 | 71530 | 66685 | 63350668 |
| Biopsy liver | 21.41 | 18.68 | 10 | 71659 | 391 | 63416962 |
| Arthralgia | 21.37 | 18.68 | 815 | 70854 | 568895 | 62848458 |
| Drug ineffective for unapproved indication | 21.31 | 18.68 | 6 | 71663 | 34057 | 63383296 |
| Pericardial drainage | 21.30 | 18.68 | 9 | 71660 | 276 | 63417077 |
| Obesity | 21.28 | 18.68 | 4 | 71665 | 29948 | 63387405 |
| Asthenia | 21.22 | 18.68 | 575 | 71094 | 383029 | 63034324 |
| Paraesthesia | 21.19 | 18.68 | 98 | 71571 | 156868 | 63260485 |
| Pulmonary artery dilatation | 21.18 | 18.68 | 9 | 71660 | 280 | 63417073 |
| Atrial fibrillation | 21.17 | 18.68 | 213 | 71456 | 116423 | 63300930 |
| Blood glucose increased | 21.03 | 18.68 | 39 | 71630 | 83717 | 63333636 |
| Inflammation | 20.94 | 18.68 | 38 | 71631 | 82235 | 63335118 |
| Device related infection | 20.88 | 18.68 | 66 | 71603 | 23326 | 63394027 |
| Cardiac failure acute | 20.74 | 18.68 | 38 | 71631 | 9485 | 63407868 |
| Catheter site pruritus | 20.72 | 18.68 | 18 | 71651 | 2102 | 63415251 |
| Encephalopathy | 20.41 | 18.68 | 9 | 71660 | 38611 | 63378742 |
| Catheter site rash | 20.33 | 18.68 | 12 | 71657 | 761 | 63416592 |
| Cerebrovascular accident | 20.14 | 18.68 | 59 | 71610 | 107965 | 63309388 |
| Osteoporosis | 20.10 | 18.68 | 21 | 71648 | 57317 | 63360036 |
| Abdominal discomfort | 20.08 | 18.68 | 489 | 71180 | 320396 | 63096957 |
| Hypoglycaemia | 19.95 | 18.68 | 23 | 71646 | 60042 | 63357311 |
| Respiratory failure | 19.95 | 18.68 | 189 | 71480 | 101669 | 63315684 |
| Diagnostic procedure | 19.89 | 18.68 | 7 | 71662 | 129 | 63417224 |
| Emotional distress | 19.88 | 18.68 | 6 | 71663 | 32543 | 63384810 |
| Skin exfoliation | 19.87 | 18.68 | 12 | 71657 | 43090 | 63374263 |
| Echocardiogram | 19.85 | 18.68 | 5 | 71664 | 26 | 63417327 |
| Myocardial infarction | 19.77 | 18.68 | 53 | 71616 | 99840 | 63317513 |
| Pulmonary hypertensive crisis | 19.68 | 18.68 | 9 | 71660 | 335 | 63417018 |
| Oral herpes | 19.59 | 18.68 | 3 | 71666 | 26071 | 63391282 |
| Premature delivery | 19.58 | 18.68 | 5 | 71664 | 30276 | 63387077 |
| Lymphocyte count decreased | 19.55 | 18.68 | 5 | 71664 | 30252 | 63387101 |
| Pulmonary endarterectomy | 19.55 | 18.68 | 7 | 71662 | 136 | 63417217 |
| Gastrointestinal surgery | 19.29 | 18.68 | 8 | 71661 | 234 | 63417119 |
| Hypocalcaemia | 19.09 | 18.68 | 6 | 71663 | 31707 | 63385646 |
| Lung disorder | 19.04 | 18.68 | 128 | 71541 | 62133 | 63355220 |
| Feeding tube user | 18.97 | 18.68 | 5 | 71664 | 32 | 63417321 |
| Paranasal sinus discomfort | 18.88 | 18.68 | 24 | 71645 | 4352 | 63413001 |
| Infusion site discharge | 18.88 | 18.68 | 11 | 71658 | 681 | 63416672 |
| Pregnancy | 18.82 | 18.68 | 9 | 71660 | 36827 | 63380526 |
| Transaminases increased | 18.76 | 18.68 | 6 | 71663 | 31361 | 63385992 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pain in jaw | 1071.64 | 23.07 | 377 | 21955 | 12663 | 34921936 |
| Headache | 1027.75 | 23.07 | 916 | 21416 | 199719 | 34734880 |
| Diarrhoea | 413.55 | 23.07 | 820 | 21512 | 389092 | 34545507 |
| Dyspnoea | 400.12 | 23.07 | 793 | 21539 | 375989 | 34558610 |
| Myalgia | 388.28 | 23.07 | 364 | 21968 | 83746 | 34850853 |
| Fluid retention | 366.82 | 23.07 | 223 | 22109 | 26664 | 34907935 |
| Hospitalisation | 306.97 | 23.07 | 269 | 22063 | 56633 | 34877966 |
| Right ventricular failure | 284.51 | 23.07 | 130 | 22202 | 8654 | 34925945 |
| Pain in extremity | 245.45 | 23.07 | 350 | 21982 | 126163 | 34808436 |
| Pulmonary hypertension | 233.76 | 23.07 | 153 | 22179 | 20771 | 34913828 |
| Flushing | 215.44 | 23.07 | 173 | 22159 | 32247 | 34902352 |
| Dyspnoea exertional | 192.95 | 23.07 | 184 | 22148 | 43095 | 34891504 |
| Death | 151.60 | 23.07 | 576 | 21756 | 397473 | 34537126 |
| Oxygen saturation decreased | 144.60 | 23.07 | 175 | 22157 | 53643 | 34880956 |
| Drug ineffective | 142.96 | 23.07 | 57 | 22275 | 456694 | 34477905 |
| Therapy change | 133.60 | 23.07 | 56 | 22276 | 3021 | 34931578 |
| Toxicity to various agents | 114.09 | 23.07 | 3 | 22329 | 200359 | 34734240 |
| Nausea | 113.08 | 23.07 | 472 | 21860 | 339436 | 34595163 |
| Arthralgia | 111.15 | 23.07 | 297 | 22035 | 169744 | 34764855 |
| Catheterisation cardiac | 110.49 | 23.07 | 47 | 22285 | 2630 | 34931969 |
| Abdominal discomfort | 99.12 | 23.07 | 154 | 22178 | 59681 | 34874918 |
| Transfusion | 96.36 | 23.07 | 63 | 22269 | 8522 | 34926077 |
| Hypervolaemia | 95.82 | 23.07 | 88 | 22244 | 19621 | 34914978 |
| Concomitant disease aggravated | 92.62 | 23.07 | 53 | 22279 | 5648 | 34928951 |
| Drug interaction | 91.35 | 23.07 | 17 | 22315 | 225929 | 34708670 |
| Oedema | 90.51 | 23.07 | 128 | 22204 | 45613 | 34888986 |
| Peripheral swelling | 82.45 | 23.07 | 163 | 22169 | 76378 | 34858221 |
| Dizziness | 77.57 | 23.07 | 310 | 22022 | 218211 | 34716388 |
| Oxygen consumption increased | 77.01 | 23.07 | 30 | 22302 | 1336 | 34933263 |
| Faeces soft | 74.68 | 23.07 | 39 | 22293 | 3469 | 34931130 |
| Brain natriuretic peptide increased | 74.66 | 23.07 | 46 | 22286 | 5613 | 34928986 |
| Acute kidney injury | 70.71 | 23.07 | 55 | 22277 | 304933 | 34629666 |
| Hypotension | 69.69 | 23.07 | 303 | 22029 | 221346 | 34713253 |
| Pulmonary arterial hypertension | 65.24 | 23.07 | 50 | 22282 | 8689 | 34925910 |
| Nasal congestion | 65.17 | 23.07 | 77 | 22255 | 22980 | 34911619 |
| Malaise | 64.59 | 23.07 | 262 | 22070 | 185563 | 34749036 |
| Thrombocytopenia | 62.57 | 23.07 | 12 | 22320 | 156235 | 34778364 |
| Pain | 59.92 | 23.07 | 274 | 22058 | 204401 | 34730198 |
| Adverse event | 58.31 | 23.07 | 66 | 22266 | 18811 | 34915788 |
| Off label use | 57.96 | 23.07 | 113 | 22219 | 419411 | 34515188 |
| Migraine | 55.51 | 23.07 | 62 | 22270 | 17416 | 34917183 |
| Feeling abnormal | 53.39 | 23.07 | 122 | 22210 | 63113 | 34871486 |
| Unevaluable event | 52.69 | 23.07 | 83 | 22249 | 32507 | 34902092 |
| Pulmonary arterial pressure increased | 51.51 | 23.07 | 22 | 22310 | 1243 | 34933356 |
| Lung transplant | 50.35 | 23.07 | 25 | 22307 | 1999 | 34932600 |
| Cardiac failure | 44.68 | 23.07 | 144 | 22188 | 91104 | 34843495 |
| Oedema peripheral | 44.01 | 23.07 | 172 | 22160 | 119640 | 34814959 |
| Condition aggravated | 43.27 | 23.07 | 239 | 22093 | 191957 | 34742642 |
| Hypoxia | 42.90 | 23.07 | 103 | 22229 | 54992 | 34879607 |
| Abdominal distension | 39.92 | 23.07 | 104 | 22228 | 58388 | 34876211 |
| Product use in unapproved indication | 39.36 | 23.07 | 13 | 22319 | 117486 | 34817113 |
| Transplant evaluation | 39.09 | 23.07 | 14 | 22318 | 492 | 34934107 |
| Pancytopenia | 38.73 | 23.07 | 7 | 22325 | 95150 | 34839449 |
| Therapy non-responder | 38.10 | 23.07 | 80 | 22252 | 39066 | 34895533 |
| Dialysis | 37.73 | 23.07 | 41 | 22291 | 11167 | 34923432 |
| Catheter management | 36.72 | 23.07 | 16 | 22316 | 949 | 34933650 |
| Neck pain | 36.14 | 23.07 | 61 | 22271 | 25288 | 34909311 |
| Syncope | 35.79 | 23.07 | 134 | 22198 | 91317 | 34843282 |
| Pulmonary veno-occlusive disease | 34.65 | 23.07 | 13 | 22319 | 522 | 34934077 |
| Decreased appetite | 34.19 | 23.07 | 202 | 22130 | 166190 | 34768409 |
| White blood cell count decreased | 32.95 | 23.07 | 10 | 22322 | 95435 | 34839164 |
| Overdose | 32.43 | 23.07 | 9 | 22323 | 91050 | 34843549 |
| Oxygen therapy | 31.33 | 23.07 | 14 | 22318 | 882 | 34933717 |
| Myocardial infarction | 30.38 | 23.07 | 20 | 22312 | 121065 | 34813534 |
| Paracentesis | 29.62 | 23.07 | 11 | 22321 | 429 | 34934170 |
| Nasopharyngitis | 29.45 | 23.07 | 105 | 22227 | 69863 | 34864736 |
| Infusion site pain | 28.67 | 23.07 | 22 | 22310 | 3829 | 34930770 |
| Hospice care | 28.05 | 23.07 | 28 | 22304 | 6912 | 34927687 |
| Pulmonary oedema | 27.92 | 23.07 | 80 | 22252 | 47449 | 34887150 |
| Intentional product use issue | 27.61 | 23.07 | 3 | 22329 | 59813 | 34874786 |
| Drug hypersensitivity | 26.80 | 23.07 | 9 | 22323 | 80520 | 34854079 |
| Limb discomfort | 26.53 | 23.07 | 34 | 22298 | 11013 | 34923586 |
| Walking distance test abnormal | 25.93 | 23.07 | 8 | 22324 | 175 | 34934424 |
| Dyspepsia | 25.76 | 23.07 | 66 | 22266 | 36666 | 34897933 |
| Abdominal pain upper | 25.70 | 23.07 | 102 | 22230 | 71388 | 34863211 |
| Confusional state | 25.31 | 23.07 | 33 | 22299 | 144127 | 34790472 |
| Weight increased | 25.26 | 23.07 | 122 | 22210 | 92911 | 34841688 |
| Blood pressure decreased | 24.92 | 23.07 | 81 | 22251 | 51434 | 34883165 |
| Pulmonary arterial wedge pressure increased | 24.91 | 23.07 | 7 | 22325 | 109 | 34934490 |
| Hyponatraemia | 24.61 | 23.07 | 11 | 22321 | 82680 | 34851919 |
| Deep vein thrombosis | 24.08 | 23.07 | 6 | 22326 | 65242 | 34869357 |
| Terminal state | 24.00 | 23.07 | 20 | 22312 | 3914 | 34930685 |
| Pericardial effusion | 23.52 | 23.07 | 50 | 22282 | 24612 | 34909987 |
| Fatigue | 23.45 | 23.07 | 349 | 21983 | 370304 | 34564295 |
| Catheter placement | 23.30 | 23.07 | 11 | 22321 | 787 | 34933812 |
| Multiple organ dysfunction syndrome | 23.07 | 23.07 | 10 | 22322 | 76556 | 34858043 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Headache | 3345.30 | 19.68 | 3737 | 79813 | 650035 | 79010803 |
| Pain in jaw | 3334.16 | 19.68 | 1389 | 82161 | 44762 | 79616076 |
| Myalgia | 1329.56 | 19.68 | 1278 | 82272 | 184363 | 79476475 |
| Diarrhoea | 1313.36 | 19.68 | 2853 | 80697 | 877636 | 78783202 |
| Dyspnoea | 1162.25 | 19.68 | 2675 | 80875 | 854350 | 78806488 |
| Fluid retention | 1090.39 | 19.68 | 758 | 82792 | 69051 | 79591787 |
| Hospitalisation | 795.66 | 19.68 | 712 | 82838 | 93524 | 79567314 |
| Dyspnoea exertional | 733.28 | 19.68 | 657 | 82893 | 86416 | 79574422 |
| Nausea | 681.63 | 19.68 | 2369 | 81181 | 954827 | 78706011 |
| Right ventricular failure | 668.92 | 19.68 | 374 | 83176 | 23123 | 79637715 |
| Drug ineffective | 653.39 | 19.68 | 166 | 83384 | 1080747 | 78580091 |
| Flushing | 619.74 | 19.68 | 602 | 82948 | 87666 | 79573172 |
| Pain in extremity | 566.71 | 19.68 | 1206 | 82344 | 363332 | 79297506 |
| Pulmonary hypertension | 524.04 | 19.68 | 421 | 83129 | 47659 | 79613179 |
| Death | 480.75 | 19.68 | 1491 | 82059 | 565023 | 79095815 |
| Transfusion | 445.55 | 19.68 | 278 | 83272 | 21052 | 79639786 |
| Oxygen saturation decreased | 405.40 | 19.68 | 583 | 82967 | 128464 | 79532374 |
| Toxicity to various agents | 398.74 | 19.68 | 9 | 83541 | 421531 | 79239307 |
| Off label use | 364.24 | 19.68 | 254 | 83296 | 906961 | 78753877 |
| Therapy change | 362.84 | 19.68 | 170 | 83380 | 7229 | 79653609 |
| Oxygen consumption increased | 332.49 | 19.68 | 142 | 83408 | 4837 | 79656001 |
| Unevaluable event | 318.61 | 19.68 | 340 | 83210 | 55245 | 79605593 |
| Hypervolaemia | 312.27 | 19.68 | 298 | 83252 | 42392 | 79618446 |
| Dizziness | 308.39 | 19.68 | 1227 | 82323 | 525214 | 79135624 |
| Drug interaction | 295.74 | 19.68 | 42 | 83508 | 415141 | 79245697 |
| Neutropenia | 272.46 | 19.68 | 6 | 83544 | 287704 | 79373134 |
| Catheterisation cardiac | 266.72 | 19.68 | 127 | 83423 | 5601 | 79655237 |
| Nasal congestion | 236.05 | 19.68 | 343 | 83207 | 76209 | 79584629 |
| Pulmonary arterial pressure increased | 233.72 | 19.68 | 108 | 83442 | 4447 | 79656391 |
| Concomitant disease aggravated | 229.05 | 19.68 | 153 | 83397 | 13014 | 79647824 |
| Oedema | 228.59 | 19.68 | 432 | 83118 | 119148 | 79541690 |
| Hypotension | 228.20 | 19.68 | 989 | 82561 | 439328 | 79221510 |
| Pulmonary arterial hypertension | 211.20 | 19.68 | 200 | 83350 | 28166 | 79632672 |
| Decreased appetite | 205.55 | 19.68 | 805 | 82745 | 341613 | 79319225 |
| Malaise | 205.13 | 19.68 | 1034 | 82516 | 488835 | 79172003 |
| Acute kidney injury | 201.83 | 19.68 | 150 | 83400 | 519254 | 79141584 |
| Brain natriuretic peptide increased | 201.11 | 19.68 | 122 | 83428 | 8778 | 79652060 |
| Feeling abnormal | 191.58 | 19.68 | 477 | 83073 | 158722 | 79502116 |
| Product dose omission issue | 173.53 | 19.68 | 612 | 82938 | 246925 | 79413913 |
| Thrombocytopenia | 170.75 | 19.68 | 35 | 83515 | 265224 | 79395614 |
| Drug hypersensitivity | 170.03 | 19.68 | 51 | 83499 | 298865 | 79361973 |
| Oedema peripheral | 167.70 | 19.68 | 613 | 82937 | 251675 | 79409163 |
| Treatment failure | 159.61 | 19.68 | 4 | 83546 | 170482 | 79490356 |
| Cardiac failure | 156.73 | 19.68 | 435 | 83115 | 154407 | 79506431 |
| Drug abuse | 147.97 | 19.68 | 5 | 83545 | 162686 | 79498152 |
| Pain | 140.27 | 19.68 | 1234 | 82316 | 702568 | 78958270 |
| Product use in unapproved indication | 134.78 | 19.68 | 47 | 83503 | 250312 | 79410526 |
| Rheumatoid arthritis | 133.12 | 19.68 | 28 | 83522 | 208442 | 79452396 |
| Rash | 132.73 | 19.68 | 253 | 83297 | 578105 | 79082733 |
| Syncope | 132.03 | 19.68 | 451 | 83099 | 178998 | 79481840 |
| Faeces soft | 128.84 | 19.68 | 90 | 83460 | 8233 | 79652605 |
| Abdominal discomfort | 128.64 | 19.68 | 562 | 82988 | 250165 | 79410673 |
| Malignant neoplasm progression | 128.02 | 19.68 | 3 | 83547 | 135987 | 79524851 |
| Maternal exposure during pregnancy | 124.86 | 19.68 | 4 | 83546 | 136534 | 79524304 |
| Palpitations | 122.51 | 19.68 | 350 | 83200 | 126260 | 79534578 |
| Abdominal distension | 120.90 | 19.68 | 336 | 83214 | 119314 | 79541524 |
| Hepatic enzyme increased | 117.67 | 19.68 | 24 | 83526 | 182586 | 79478252 |
| Chest pain | 116.49 | 19.68 | 594 | 82956 | 281710 | 79379128 |
| Scleroderma | 115.49 | 19.68 | 72 | 83478 | 5438 | 79655400 |
| Arthropathy | 114.70 | 19.68 | 23 | 83527 | 177088 | 79483750 |
| Hypoxia | 112.38 | 19.68 | 298 | 83252 | 102945 | 79557893 |
| Intentional product use issue | 111.45 | 19.68 | 14 | 83536 | 152098 | 79508740 |
| Neck pain | 111.43 | 19.68 | 245 | 83305 | 75172 | 79585666 |
| Oxygen therapy | 109.35 | 19.68 | 55 | 83495 | 2735 | 79658103 |
| Therapeutic product effect incomplete | 106.34 | 19.68 | 12 | 83538 | 141633 | 79519205 |
| Alopecia | 104.55 | 19.68 | 56 | 83494 | 231299 | 79429539 |
| Lung transplant | 104.27 | 19.68 | 63 | 83487 | 4498 | 79656340 |
| Stomatitis | 103.97 | 19.68 | 15 | 83535 | 146742 | 79514096 |
| Peripheral swelling | 102.07 | 19.68 | 554 | 82996 | 269063 | 79391775 |
| Vomiting | 101.85 | 19.68 | 1105 | 82445 | 664723 | 78996115 |
| Hypersensitivity | 101.32 | 19.68 | 76 | 83474 | 262163 | 79398675 |
| Walking distance test abnormal | 99.22 | 19.68 | 35 | 83515 | 703 | 79660135 |
| Dyspepsia | 98.92 | 19.68 | 294 | 83256 | 108393 | 79552445 |
| Migraine | 97.72 | 19.68 | 255 | 83295 | 87238 | 79573600 |
| Intentional overdose | 97.25 | 19.68 | 3 | 83547 | 105957 | 79554881 |
| Leukopenia | 95.14 | 19.68 | 7 | 83543 | 116506 | 79544332 |
| Overdose | 95.03 | 19.68 | 37 | 83513 | 184169 | 79476669 |
| Rhabdomyolysis | 94.37 | 19.68 | 3 | 83547 | 103128 | 79557710 |
| Pulmonary veno-occlusive disease | 93.78 | 19.68 | 42 | 83508 | 1606 | 79659232 |
| Hypertension | 92.50 | 19.68 | 127 | 83423 | 330865 | 79329973 |
| Blood pressure decreased | 92.37 | 19.68 | 271 | 83279 | 99195 | 79561643 |
| Arthralgia | 92.06 | 19.68 | 959 | 82591 | 570844 | 79089994 |
| Confusional state | 91.93 | 19.68 | 119 | 83431 | 317878 | 79342960 |
| Abdominal pain upper | 90.92 | 19.68 | 469 | 83081 | 223350 | 79437488 |
| Pulmonary oedema | 87.32 | 19.68 | 246 | 83304 | 88008 | 79572830 |
| Transplant evaluation | 86.32 | 19.68 | 40 | 83510 | 1657 | 79659181 |
| Pericarditis | 85.87 | 19.68 | 6 | 83544 | 104230 | 79556608 |
| Neutrophil count decreased | 85.03 | 19.68 | 3 | 83547 | 93956 | 79566882 |
| Hospice care | 83.02 | 19.68 | 76 | 83474 | 10248 | 79650590 |
| Glossodynia | 82.16 | 19.68 | 7 | 83543 | 103330 | 79557508 |
| Blister | 80.58 | 19.68 | 14 | 83536 | 119462 | 79541376 |
| Infusion site pain | 79.91 | 19.68 | 86 | 83464 | 14090 | 79646748 |
| Fatigue | 79.72 | 19.68 | 1391 | 82159 | 928336 | 78732502 |
| Therapy non-responder | 79.58 | 19.68 | 245 | 83305 | 92060 | 79568778 |
| Coma | 79.52 | 19.68 | 7 | 83543 | 100642 | 79560196 |
| Joint swelling | 79.39 | 19.68 | 112 | 83438 | 288534 | 79372304 |
| Hyponatraemia | 78.95 | 19.68 | 44 | 83506 | 177804 | 79483034 |
| Paracentesis | 78.85 | 19.68 | 35 | 83515 | 1310 | 79659528 |
| Dialysis | 77.17 | 19.68 | 96 | 83454 | 18366 | 79642472 |
| Impaired healing | 75.35 | 19.68 | 4 | 83546 | 87651 | 79573187 |
| Condition aggravated | 75.24 | 19.68 | 829 | 82721 | 500295 | 79160543 |
| Pancytopenia | 75.03 | 19.68 | 40 | 83510 | 165705 | 79495133 |
| Insomnia | 74.78 | 19.68 | 476 | 83074 | 244694 | 79416144 |
| Bedridden | 74.72 | 19.68 | 77 | 83473 | 12002 | 79648836 |
| Pneumonia | 74.49 | 19.68 | 1035 | 82515 | 659211 | 79001627 |
| Dyspnoea at rest | 73.31 | 19.68 | 61 | 83489 | 7241 | 79653597 |
| Chest discomfort | 72.67 | 19.68 | 312 | 83238 | 137732 | 79523106 |
| N-terminal prohormone brain natriuretic peptide increased | 72.62 | 19.68 | 51 | 83499 | 4704 | 79656134 |
| Pericardial effusion | 72.62 | 19.68 | 154 | 83396 | 46083 | 79614755 |
| Catheter management | 72.10 | 19.68 | 46 | 83504 | 3617 | 79657221 |
| Drug titration error | 70.58 | 19.68 | 31 | 83519 | 1131 | 79659707 |
| Seizure | 70.03 | 19.68 | 57 | 83493 | 188777 | 79472061 |
| Cough | 68.58 | 19.68 | 635 | 82915 | 366154 | 79294684 |
| Head discomfort | 68.11 | 19.68 | 80 | 83470 | 14422 | 79646416 |
| Electrocardiogram QT prolonged | 66.97 | 19.68 | 8 | 83542 | 90378 | 79570460 |
| Catheter site pain | 66.84 | 19.68 | 51 | 83499 | 5345 | 79655493 |
| C-reactive protein increased | 66.39 | 19.68 | 26 | 83524 | 129001 | 79531837 |
| Dizziness postural | 64.99 | 19.68 | 70 | 83480 | 11479 | 79649359 |
| Cardioversion | 64.08 | 19.68 | 35 | 83515 | 2063 | 79658775 |
| Muscle spasms | 64.01 | 19.68 | 356 | 83194 | 174374 | 79486464 |
| Urticaria | 62.56 | 19.68 | 61 | 83489 | 185140 | 79475698 |
| Epistaxis | 61.76 | 19.68 | 256 | 83294 | 111259 | 79549579 |
| Psoriasis | 61.51 | 19.68 | 10 | 83540 | 89577 | 79571261 |
| Deep vein thrombosis | 61.18 | 19.68 | 25 | 83525 | 120894 | 79539944 |
| Bradycardia | 60.93 | 19.68 | 33 | 83517 | 135524 | 79525314 |
| Ascites | 60.93 | 19.68 | 196 | 83354 | 75366 | 79585472 |
| Blood cholesterol increased | 60.60 | 19.68 | 8 | 83542 | 83712 | 79577126 |
| Catheter placement | 60.16 | 19.68 | 38 | 83512 | 2936 | 79657902 |
| Back pain | 59.06 | 19.68 | 531 | 83019 | 303649 | 79357189 |
| Lower respiratory tract infection | 58.75 | 19.68 | 31 | 83519 | 129189 | 79531649 |
| Atrial septal defect repair | 58.75 | 19.68 | 21 | 83529 | 439 | 79660399 |
| White blood cell count decreased | 56.95 | 19.68 | 68 | 83482 | 188220 | 79472618 |
| Blood creatine phosphokinase increased | 56.85 | 19.68 | 3 | 83547 | 66087 | 79594751 |
| Myocardial infarction | 56.22 | 19.68 | 66 | 83484 | 184063 | 79476775 |
| Productive cough | 55.53 | 19.68 | 211 | 83339 | 88120 | 79572718 |
| Disease complication | 55.38 | 19.68 | 44 | 83506 | 4893 | 79655945 |
| Agitation | 54.86 | 19.68 | 18 | 83532 | 99697 | 79561141 |
| Helicobacter infection | 54.65 | 19.68 | 5 | 83545 | 69699 | 79591139 |
| Intentional product misuse | 54.47 | 19.68 | 16 | 83534 | 95149 | 79565689 |
| Asthma | 52.33 | 19.68 | 39 | 83511 | 135056 | 79525782 |
| Liver function test abnormal | 52.27 | 19.68 | 4 | 83546 | 64471 | 79596367 |
| Mobility decreased | 51.70 | 19.68 | 32 | 83518 | 122143 | 79538695 |
| Suicidal ideation | 49.22 | 19.68 | 10 | 83540 | 76330 | 79584508 |
| Extra dose administered | 49.11 | 19.68 | 52 | 83498 | 8363 | 79652475 |
| Musculoskeletal stiffness | 48.99 | 19.68 | 67 | 83483 | 174941 | 79485897 |
| Angioedema | 48.94 | 19.68 | 10 | 83540 | 76025 | 79584813 |
| Depressed level of consciousness | 48.86 | 19.68 | 20 | 83530 | 96632 | 79564206 |
| General physical health deterioration | 48.80 | 19.68 | 138 | 83412 | 275100 | 79385738 |
| Pruritus | 48.78 | 19.68 | 230 | 83320 | 394418 | 79266420 |
| Left ventricular failure | 48.60 | 19.68 | 55 | 83495 | 9526 | 79651312 |
| Injection site pain | 48.37 | 19.68 | 39 | 83511 | 129799 | 79531039 |
| Hyperkalaemia | 48.35 | 19.68 | 30 | 83520 | 114368 | 79546470 |
| Lactic acidosis | 47.98 | 19.68 | 8 | 83542 | 70351 | 79590487 |
| Cognitive disorder | 47.57 | 19.68 | 8 | 83542 | 69918 | 79590920 |
| Wound | 47.02 | 19.68 | 32 | 83518 | 116147 | 79544691 |
| Metabolic acidosis | 47.01 | 19.68 | 14 | 83536 | 82515 | 79578323 |
| Mineral supplementation | 46.50 | 19.68 | 21 | 83529 | 819 | 79660019 |
| Pulmonary embolism | 45.79 | 19.68 | 68 | 83482 | 171586 | 79489252 |
| Weight decreased | 44.97 | 19.68 | 569 | 82981 | 354629 | 79306209 |
| Catheter site erythema | 44.94 | 19.68 | 40 | 83510 | 5200 | 79655638 |
| Liver injury | 44.55 | 19.68 | 4 | 83546 | 56610 | 79604228 |
| Pyrexia | 43.97 | 19.68 | 477 | 83073 | 678232 | 78982606 |
| Multiple organ dysfunction syndrome | 43.70 | 19.68 | 37 | 83513 | 120209 | 79540629 |
| Acute myocardial infarction | 42.21 | 19.68 | 14 | 83536 | 77022 | 79583816 |
| Flatulence | 42.15 | 19.68 | 119 | 83431 | 42605 | 79618233 |
| Heart rate increased | 41.58 | 19.68 | 242 | 83308 | 120482 | 79540356 |
| Presyncope | 41.14 | 19.68 | 115 | 83435 | 40939 | 79619899 |
| Nasopharyngitis | 40.78 | 19.68 | 426 | 83124 | 253455 | 79407383 |
| Discomfort | 40.56 | 19.68 | 43 | 83507 | 125574 | 79535264 |
| Cardiac operation | 40.50 | 19.68 | 37 | 83513 | 4975 | 79655863 |
| Cerebrovascular accident | 39.99 | 19.68 | 63 | 83487 | 155229 | 79505609 |
| Blood pressure increased | 39.69 | 19.68 | 103 | 83447 | 211257 | 79449581 |
| Coronary artery disease | 39.36 | 19.68 | 10 | 83540 | 65464 | 79595374 |
| Pulmonary arterial pressure abnormal | 39.34 | 19.68 | 18 | 83532 | 724 | 79660114 |
| Terminal state | 39.33 | 19.68 | 36 | 83514 | 4853 | 79655985 |
| Encephalopathy | 39.18 | 19.68 | 11 | 83539 | 67386 | 79593452 |
| Iron deficiency anaemia | 38.58 | 19.68 | 84 | 83466 | 25588 | 79635250 |
| Hypoglycaemia | 38.49 | 19.68 | 30 | 83520 | 101564 | 79559274 |
| Hallucination | 38.34 | 19.68 | 21 | 83529 | 85724 | 79575114 |
| Cardiac disorder | 38.01 | 19.68 | 153 | 83397 | 65604 | 79595234 |
| Adverse event | 37.97 | 19.68 | 144 | 83406 | 60070 | 79600768 |
| Limb discomfort | 37.95 | 19.68 | 97 | 83453 | 32753 | 79628085 |
| Injection site reaction | 37.87 | 19.68 | 6 | 83544 | 54779 | 79606059 |
| Injury | 37.64 | 19.68 | 17 | 83533 | 77479 | 79583359 |
| Multiple sclerosis relapse | 37.40 | 19.68 | 3 | 83547 | 46530 | 79614308 |
| Osteoarthritis | 36.75 | 19.68 | 23 | 83527 | 87286 | 79573552 |
| Injection site erythema | 36.68 | 19.68 | 18 | 83532 | 78179 | 79582659 |
| Plasma cell myeloma | 36.44 | 19.68 | 6 | 83544 | 53253 | 79607585 |
| Cardiac ablation | 36.36 | 19.68 | 25 | 83525 | 2228 | 79658610 |
| Drug-induced liver injury | 36.25 | 19.68 | 12 | 83538 | 66105 | 79594733 |
| Delirium | 36.03 | 19.68 | 22 | 83528 | 84605 | 79576233 |
| Product use issue | 35.87 | 19.68 | 107 | 83443 | 209715 | 79451123 |
| Systemic lupus erythematosus | 35.31 | 19.68 | 45 | 83505 | 121104 | 79539734 |
| Atrial septal defect | 35.03 | 19.68 | 23 | 83527 | 1899 | 79658939 |
| Right ventricular dilatation | 34.99 | 19.68 | 23 | 83527 | 1903 | 79658935 |
| Gout | 34.96 | 19.68 | 79 | 83471 | 24670 | 79636168 |
| Alanine aminotransferase increased | 34.69 | 19.68 | 74 | 83476 | 162496 | 79498342 |
| Hepatitis | 34.50 | 19.68 | 8 | 83542 | 55719 | 79605119 |
| Pneumonitis | 33.45 | 19.68 | 11 | 83539 | 60849 | 79599989 |
| Pulmonary artery dilatation | 33.39 | 19.68 | 14 | 83536 | 455 | 79660383 |
| Exposure during pregnancy | 33.34 | 19.68 | 34 | 83516 | 101098 | 79559740 |
| Hypocalcaemia | 33.33 | 19.68 | 6 | 83544 | 49918 | 79610920 |
| Hyperglycaemia | 33.28 | 19.68 | 16 | 83534 | 70319 | 79590519 |
| Wrong dose | 32.66 | 19.68 | 21 | 83529 | 1673 | 79659165 |
| Disease recurrence | 32.44 | 19.68 | 4 | 83546 | 44105 | 79616733 |
| Drug ineffective for unapproved indication | 32.44 | 19.68 | 7 | 83543 | 51231 | 79609607 |
| Disease progression | 32.30 | 19.68 | 315 | 83235 | 184047 | 79476791 |
| Catheterisation cardiac abnormal | 31.98 | 19.68 | 12 | 83538 | 289 | 79660549 |
| Type 2 diabetes mellitus | 31.97 | 19.68 | 10 | 83540 | 57112 | 79603726 |
| Renal disorder | 31.95 | 19.68 | 107 | 83443 | 41998 | 79618840 |
| Abdominal cavity drainage | 31.47 | 19.68 | 16 | 83534 | 814 | 79660024 |
| Septic shock | 31.44 | 19.68 | 50 | 83500 | 122751 | 79538087 |
| Right ventricular enlargement | 31.36 | 19.68 | 15 | 83535 | 668 | 79660170 |
| Pulmonary congestion | 31.28 | 19.68 | 80 | 83470 | 27020 | 79633818 |
| Neuropathy peripheral | 31.26 | 19.68 | 63 | 83487 | 141242 | 79519596 |
| Eosinophilia | 31.26 | 19.68 | 5 | 83545 | 45340 | 79615498 |
| Systemic scleroderma | 31.21 | 19.68 | 18 | 83532 | 1179 | 79659659 |
| Cytomegalovirus infection | 31.04 | 19.68 | 4 | 83546 | 42640 | 79618198 |
| Swollen tongue | 30.97 | 19.68 | 4 | 83546 | 42566 | 79618272 |
| Nocturnal dyspnoea | 30.97 | 19.68 | 20 | 83530 | 1606 | 79659232 |
| Cardiac failure high output | 30.91 | 19.68 | 12 | 83538 | 318 | 79660520 |
| Rehabilitation therapy | 30.70 | 19.68 | 21 | 83529 | 1856 | 79658982 |
| Respiratory arrest | 30.60 | 19.68 | 11 | 83539 | 57539 | 79603299 |
| Haemodynamic test abnormal | 30.57 | 19.68 | 8 | 83542 | 54 | 79660784 |
| Blood pressure systolic increased | 30.54 | 19.68 | 16 | 83534 | 66970 | 79593868 |
| Jaundice | 30.47 | 19.68 | 9 | 83541 | 53340 | 79607498 |
| Right-to-left cardiac shunt | 30.29 | 19.68 | 11 | 83539 | 241 | 79660597 |
| Skin exfoliation | 30.21 | 19.68 | 10 | 83540 | 55090 | 79605748 |
| Blood lactate dehydrogenase increased | 30.20 | 19.68 | 3 | 83547 | 39167 | 79621671 |
| Emergency care | 30.14 | 19.68 | 17 | 83533 | 1067 | 79659771 |
| Exercise tolerance decreased | 29.92 | 19.68 | 42 | 83508 | 9029 | 79651809 |
| Pulmonary hypertensive crisis | 29.90 | 19.68 | 12 | 83538 | 348 | 79660490 |
| Psychotic disorder | 29.85 | 19.68 | 4 | 83546 | 41398 | 79619440 |
| Altered state of consciousness | 29.84 | 19.68 | 5 | 83545 | 43817 | 79617021 |
| Oxygen saturation abnormal | 29.78 | 19.68 | 30 | 83520 | 4552 | 79656286 |
| Haemoptysis | 29.77 | 19.68 | 127 | 83423 | 55872 | 79604966 |
| Irritable bowel syndrome | 29.69 | 19.68 | 14 | 83536 | 62227 | 79598611 |
| Influenza like illness | 29.57 | 19.68 | 151 | 83399 | 71556 | 79589282 |
| Cardiac output increased | 29.32 | 19.68 | 11 | 83539 | 265 | 79660573 |
| Influenza | 29.19 | 19.68 | 234 | 83316 | 129372 | 79531466 |
| Endarterectomy | 29.18 | 19.68 | 12 | 83538 | 371 | 79660467 |
| Stent placement | 29.02 | 19.68 | 35 | 83515 | 6485 | 79654353 |
| Pancreatitis acute | 29.01 | 19.68 | 8 | 83542 | 49596 | 79611242 |
| Medication error | 29.00 | 19.68 | 18 | 83532 | 68624 | 79592214 |
| Right ventricular dysfunction | 28.52 | 19.68 | 23 | 83527 | 2612 | 79658226 |
| Aggression | 28.38 | 19.68 | 9 | 83541 | 50949 | 79609889 |
| Restless legs syndrome | 28.23 | 19.68 | 64 | 83486 | 20028 | 79640810 |
| Stevens-Johnson syndrome | 27.73 | 19.68 | 4 | 83546 | 39162 | 79621676 |
| Dizziness exertional | 27.56 | 19.68 | 13 | 83537 | 561 | 79660277 |
| Transaminases increased | 27.32 | 19.68 | 10 | 83540 | 51733 | 79609105 |
| Fibromyalgia | 27.01 | 19.68 | 17 | 83533 | 64323 | 79596515 |
| Mouth ulceration | 27.00 | 19.68 | 4 | 83546 | 38390 | 79622448 |
| Catheter site pruritus | 26.95 | 19.68 | 21 | 83529 | 2270 | 79658568 |
| Metapneumovirus infection | 26.93 | 19.68 | 19 | 83531 | 1765 | 79659073 |
| Hot flush | 26.55 | 19.68 | 121 | 83429 | 54756 | 79606082 |
| Biopsy liver | 26.45 | 19.68 | 13 | 83537 | 615 | 79660223 |
| Emotional distress | 26.26 | 19.68 | 5 | 83545 | 39964 | 79620874 |
| Hepatic failure | 25.93 | 19.68 | 16 | 83534 | 61196 | 79599642 |
| Skin lesion | 25.92 | 19.68 | 6 | 83544 | 41838 | 79619000 |
| Catheter site rash | 25.90 | 19.68 | 15 | 83535 | 990 | 79659848 |
| Drug withdrawal syndrome | 25.90 | 19.68 | 3 | 83547 | 34715 | 79626123 |
| Depression | 25.78 | 19.68 | 128 | 83422 | 216662 | 79444176 |
| Musculoskeletal pain | 25.38 | 19.68 | 189 | 83361 | 102165 | 79558673 |
| Facial pain | 25.29 | 19.68 | 46 | 83504 | 12304 | 79648534 |
| Haematuria | 25.23 | 19.68 | 21 | 83529 | 68815 | 79592023 |
| Lymphocyte count decreased | 25.21 | 19.68 | 9 | 83541 | 47280 | 79613558 |
| Localised oedema | 25.02 | 19.68 | 36 | 83514 | 7916 | 79652922 |
| Device related infection | 25.00 | 19.68 | 86 | 83464 | 34208 | 79626630 |
| Hemiparesis | 24.95 | 19.68 | 3 | 83547 | 33730 | 79627108 |
| Gastric disorder | 24.83 | 19.68 | 91 | 83459 | 37342 | 79623496 |
| Catheter site infection | 24.74 | 19.68 | 33 | 83517 | 6762 | 79654076 |
| Diuretic therapy | 24.66 | 19.68 | 9 | 83541 | 200 | 79660638 |
| Cardiothoracic ratio increased | 24.60 | 19.68 | 7 | 83543 | 67 | 79660771 |
| Product supply issue | 24.59 | 19.68 | 19 | 83531 | 2029 | 79658809 |
| Gastrooesophageal reflux disease | 24.45 | 19.68 | 190 | 83360 | 104056 | 79556782 |
| Prescribed overdose | 24.34 | 19.68 | 5 | 83545 | 37878 | 79622960 |
| Dysarthria | 24.33 | 19.68 | 21 | 83529 | 67601 | 79593237 |
| Acute respiratory failure | 24.29 | 19.68 | 125 | 83425 | 59416 | 79601422 |
| Bone pain | 24.13 | 19.68 | 119 | 83431 | 55623 | 79605215 |
| Pericardial drainage | 24.05 | 19.68 | 11 | 83539 | 442 | 79660396 |
| Drug eruption | 24.04 | 19.68 | 8 | 83542 | 43927 | 79616911 |
| Obesity | 23.93 | 19.68 | 4 | 83546 | 35121 | 79625717 |
| Cardiac pacemaker insertion | 23.89 | 19.68 | 30 | 83520 | 5792 | 79655046 |
| Basal cell carcinoma | 23.88 | 19.68 | 5 | 83545 | 37370 | 79623468 |
| Therapeutic response decreased | 23.76 | 19.68 | 21 | 83529 | 66832 | 79594006 |
| Hereditary haemorrhagic telangiectasia | 23.68 | 19.68 | 6 | 83544 | 35 | 79660803 |
| Infusion site discharge | 23.65 | 19.68 | 12 | 83538 | 608 | 79660230 |
| Electrocardiogram ambulatory | 23.45 | 19.68 | 4 | 83546 | 0 | 79660838 |
| Dysentery | 23.42 | 19.68 | 15 | 83535 | 1187 | 79659651 |
| Blood pressure abnormal | 23.36 | 19.68 | 54 | 83496 | 17115 | 79643723 |
| Hypomagnesaemia | 23.24 | 19.68 | 10 | 83540 | 46901 | 79613937 |
| Haemorrhoidal haemorrhage | 23.22 | 19.68 | 32 | 83518 | 6763 | 79654075 |
| Cerebral haemorrhage | 23.18 | 19.68 | 16 | 83534 | 57657 | 79603181 |
| Product prescribing error | 23.09 | 19.68 | 9 | 83541 | 44804 | 79616034 |
| Concomitant disease progression | 23.05 | 19.68 | 23 | 83527 | 3450 | 79657388 |
| Infection | 22.71 | 19.68 | 154 | 83396 | 241558 | 79419280 |
| Hyperhidrosis | 22.60 | 19.68 | 82 | 83468 | 151410 | 79509428 |
| Pulmonary arterial wedge pressure increased | 22.50 | 19.68 | 11 | 83539 | 514 | 79660324 |
| Catheter site warmth | 22.46 | 19.68 | 9 | 83541 | 260 | 79660578 |
| Joint range of motion decreased | 22.22 | 19.68 | 4 | 83546 | 33278 | 79627560 |
| Blood potassium decreased | 22.09 | 19.68 | 102 | 83448 | 46410 | 79614428 |
| Loss of consciousness | 22.05 | 19.68 | 271 | 83279 | 167672 | 79493166 |
| Wrong technique in product usage process | 21.98 | 19.68 | 27 | 83523 | 73848 | 79586990 |
| Disorientation | 21.98 | 19.68 | 20 | 83530 | 62756 | 79598082 |
| Upper respiratory tract inflammation | 21.90 | 19.68 | 24 | 83526 | 4011 | 79656827 |
| Liver transplant | 21.77 | 19.68 | 25 | 83525 | 4398 | 79656440 |
| Infusion site erythema | 21.65 | 19.68 | 37 | 83513 | 9423 | 79651415 |
| Aphasia | 21.55 | 19.68 | 11 | 83539 | 46721 | 79614117 |
| Epilepsy | 21.40 | 19.68 | 8 | 83542 | 40852 | 79619986 |
| Feeding tube user | 21.15 | 19.68 | 7 | 83543 | 115 | 79660723 |
| Urinary retention | 21.09 | 19.68 | 17 | 83533 | 56613 | 79604225 |
| Vasodilatation | 20.93 | 19.68 | 21 | 83529 | 3170 | 79657668 |
| Haemoglobin decreased | 20.93 | 19.68 | 338 | 83212 | 221781 | 79439057 |
| Retching | 20.61 | 19.68 | 52 | 83498 | 17415 | 79643423 |
| Disseminated intravascular coagulation | 20.56 | 19.68 | 6 | 83544 | 35836 | 79625002 |
| Central venous catheterisation | 20.40 | 19.68 | 21 | 83529 | 3268 | 79657570 |
| Blood iron decreased | 20.40 | 19.68 | 48 | 83502 | 15386 | 79645452 |
| Leukocytosis | 20.38 | 19.68 | 10 | 83540 | 43445 | 79617393 |
| Diplopia | 20.33 | 19.68 | 5 | 83545 | 33461 | 79627377 |
| Tracheostomy | 20.26 | 19.68 | 14 | 83536 | 1258 | 79659580 |
| N-terminal prohormone brain natriuretic peptide | 20.25 | 19.68 | 6 | 83544 | 67 | 79660771 |
| Cardiac monitoring | 20.22 | 19.68 | 5 | 83545 | 26 | 79660812 |
| Hypokalaemia | 20.17 | 19.68 | 80 | 83470 | 143960 | 79516878 |
| Bendopnoea | 20.06 | 19.68 | 5 | 83545 | 27 | 79660811 |
| Hepatic cirrhosis | 19.99 | 19.68 | 81 | 83469 | 34825 | 79626013 |
| Paranasal sinus discomfort | 19.96 | 19.68 | 24 | 83526 | 4432 | 79656406 |
| Pulmonary pain | 19.89 | 19.68 | 24 | 83526 | 4449 | 79656389 |
| Catheter site discharge | 19.87 | 19.68 | 18 | 83532 | 2394 | 79658444 |
| Inflammation | 19.72 | 19.68 | 43 | 83507 | 93710 | 79567128 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B01AC27 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
| FDA MoA | N0000020068 | Prostacyclin Receptor Agonists |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| FDA EPC | N0000192339 | Prostacyclin Receptor Agonist |
| CHEBI has role | CHEBI:35620 | vasodilator agents |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
| CHEBI has role | CHEBI:71031 | orphan drugs |
| CHEBI has role | CHEBI:90845 | prostacyclin receptor agonists |
| CHEBI has role | CHEBI:49103 | drug metabolites |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pulmonary arterial hypertension | indication | 11399002 | |
| Thromboembolic pulmonary hypertension | indication | 233947005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.49 | acidic |
| pKa2 | 5.13 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 0.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 0.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 0.8MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 1.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 1.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 1.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 1MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 1.8MG/VIAL | UPTRAVI | ACTELION | N214275 | July 29, 2021 | RX | POWDER | INTRAVENOUS | 7205302 | Oct. 31, 2026 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| 0.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 0.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 0.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 0.8MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 1.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 1.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 1.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 1MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 1.8MG/VIAL | UPTRAVI | ACTELION | N214275 | July 29, 2021 | RX | POWDER | INTRAVENOUS | 9173881 | Aug. 12, 2029 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| 0.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 0.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 0.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 0.8MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 1.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 1.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 1.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 1MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 1.8MG/VIAL | UPTRAVI | ACTELION | N214275 | July 29, 2021 | RX | POWDER | INTRAVENOUS | 9284280 | June 25, 2030 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| 0.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 0.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 0.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 0.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 0.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 0.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 0.8MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 0.8MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 1.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 1.2MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 1.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 1.4MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 1.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 1.6MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
| 1MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10821108 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG |
| 1MG | UPTRAVI | ACTELION | N207947 | Dec. 21, 2015 | RX | TABLET | ORAL | 10828298 | Dec. 1, 2036 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostacyclin receptor | GPCR | AGONIST | Ki | 7.70 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Prostaglandin E2 receptor EP2 subtype | GPCR | AGONIST | Ki | 5.24 | IUPHAR | ||||
| Prostaglandin E2 receptor EP4 subtype | GPCR | AGONIST | Ki | 5.31 | IUPHAR | ||||
| Prostaglandin D2 receptor | GPCR | EC50 | 7 | CHEMBL | |||||
| Prostacyclin receptor | GPCR | AGONIST | Ki | 5.68 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D09994 | KEGG_DRUG |
| 4035275 | VANDF |
| CHEBI:90844 | CHEBI |
| CHEBI:90848 | CHEBI |
| CHEMBL238804 | ChEMBL_ID |
| C523468 | MESH_SUPPLEMENTAL_RECORD_UI |
| C531934 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7552 | IUPHAR_LIGAND_ID |
| DB11362 | DRUGBANK_ID |
| 1729002 | RXNORM |
| 237614 | MMSL |
| 31388 | MMSL |
| d08407 | MMSL |
| 016638 | NDDF |
| 717359004 | SNOMEDCT_US |
| 781377007 | SNOMEDCT_US |
| C2000145 | UMLSCUI |
| C2606862 | UMLSCUI |
| 9231 | INN_ID |
| 9913767 | PUBCHEM_CID |
| 475085-57-5 | SECONDARY_CAS_RN |
| 9931891 | PUBCHEM_CID |
| 5852 | IUPHAR_LIGAND_ID |
| 5EXC0E384L | UNII |
| E9PC7N0DID | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-602 | TABLET, COATED | 200 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-602 | TABLET, COATED | 200 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-602 | TABLET, COATED | 200 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-604 | TABLET, COATED | 400 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-604 | TABLET, COATED | 400 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-604 | TABLET, COATED | 400 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-606 | TABLET, COATED | 600 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-606 | TABLET, COATED | 600 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-606 | TABLET, COATED | 600 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-608 | TABLET, COATED | 800 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-608 | TABLET, COATED | 800 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-608 | TABLET, COATED | 800 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-610 | TABLET, COATED | 1000 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-610 | TABLET, COATED | 1000 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-610 | TABLET, COATED | 1000 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-612 | TABLET, COATED | 1200 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-612 | TABLET, COATED | 1200 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-612 | TABLET, COATED | 1200 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-614 | TABLET, COATED | 1400 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-614 | TABLET, COATED | 1400 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-614 | TABLET, COATED | 1400 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-616 | TABLET, COATED | 1600 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-616 | TABLET, COATED | 1600 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-616 | TABLET, COATED | 1600 ug | ORAL | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-718 | INJECTION, POWDER, FOR SOLUTION | 1800 ug | INTRAVENOUS | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-718 | INJECTION, POWDER, FOR SOLUTION | 1800 ug | INTRAVENOUS | NDA | 32 sections |
| UPTRAVI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66215-718 | INJECTION, POWDER, FOR SOLUTION | 1800 ug | INTRAVENOUS | NDA | 32 sections |